Cigall Kadoch: Thank you Memorial Sloan Kettering Cancer Center for this incredible honor of the 2023 Paul Marks Prize

Cigall Kadoch recently shared a post by Memorial Sloan Kettering Cancer Center, on X/Twitter, adding:

“Thank you Memorial Sloan Kettering Cancer Center for this incredible honor of the 2023 Paul Marks Prize! I am grateful to receive this alongside two other brilliant investigators and friends. My teams will continue on our mission to advance novel biology to new medicines for patients with cancer.”

Quoting Memorial Sloan Kettering Cancer Center’s post:

“Congratulations to this year’s recipients of the 2023 Paul Marks Prize for Cancer Research: Dr. Mark Agnel Frederick Dawson, Dr. Cigall Kadoch, and Dr. Michelle Monje-Deisseroth. Read more here.”

Sources: Cigall Kadoch/Twitter and Memorial Sloan Kettering Cancer Center/Twitter

Cigall Kadoch is an Associate Professor of Pediatric Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, Affiliate Faculty of Biological Chemistry and Molecular Biology at Harvard Medical School, and Institute Member and Epigenomics Program Co-Director at the Broad Institute of MIT and Harvard. She established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies in Cancer Biology at Stanford University. In 2016, Kadoch’s research resulted in the formation of Foghorn Therapeutics, a biotechnology company that seeks to build novel therapeutic strategies based on the chromatin regulatory system. Dr. Kadoch has received numerous prestigious awards and research grants to support her academic laboratory at Harvard, including the NIH Director’s New Innovator Award, the Pew Scholar Award, the American Cancer Society Research Scholar Award, the American Association for the Advancement of Sciences (AAAS) Marin and Rose Wachtel Cancer Research Prize, and the American Association for Cancer Research (AACR) Outstanding Achievement in Basic Cancer Research Award. Additionally, over the past several years, she was named to the Forbes 30 under 30 list, MIT Technology Review 35 Innovators Under 35, Popular Science Brilliant 10, Business Insider Top 30 Young leaders in Biopharma and was recently named a Blavatnik National Awards Finalist.